Oncocyte, a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer is proud to present the #ShesMySurgeon campaign in honor of outstanding women thoracic surgeons. #ShesMySurgeon was designed to highlight women in the thoracic surgery field and lives as an ongoing social media campaign, showcasing the progress these women have made in a competitive field and ensuring more work is done to achieve equal representation for women in thoracic surgery.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- #ShesMySurgeon Social media campaign brings awareness to outstanding women surgeons and encourages equal representation in surgical field
- In the US, thoracic surgery has one of the lowest percentages of women compared to other surgical and oncology specialties.
- The #ShesMySurgeon campaign highlights outstanding surgeons with the hope of encouraging more and more women to join this crucial specialty in cancer care.
Click image above to view full announcement.
About Oncocyte
Oncocyte is a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear insights that inform critical decisions in the diagnosis, treatment, and monitoring of cancer. The Company, through its proprietary tests and pharmaceutical services business, aims to help save lives by accelerating the diagnosis of cancer and advancing cancer care. The Company’s tests provide clarity and confidence at every stage. DetermaRx™ identifies early-stage lung cancer patients who are at high risk for cancer recurrence and predicts benefit from adjuvant chemotherapy. DetermaIO™, a gene expression test currently used as a research tool in drug development, assesses the tumor microenvironment to predict response to immunotherapies. The Company’s robust pipeline of future tests also includes DetermaTx™, which will assess mutational status of a tumor, blood-based monitoring test DetermaCNI, and long-term recurrence monitoring test DetermaMx™. In addition, Oncocyte’s pharmaceutical services provide companies that are developing new cancer treatments a full suite of molecular testing services to support the drug development process.
DetermaRx, DetermaIO, DetermaTx, DetermaCNI and DetermaMx are trademarks of Oncocyte Corporation.
Media Contacts
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
Contacts:
Oncocyte Marketing
ocxmarketing@oncocyte.com
Terri Clevenger – Westwicke/ICR Healthcare PR
203.856.4326
Terri.Clevenger@icrinc.com
Source: Oncocyte
Distributed by: Reportable, Inc.
